Avantor, Inc. (NYSE: AVTR) reported financial results for the third quarter of fiscal 2026, announcing that net sales increased 4.6% to $1,698.3 million for the three months ended September 30, 2026. The company noted that organic net sales grew by 5.2%, while foreign currency translation had a negative impact of 0.6%.
For the quarter, the company reported diluted GAAP earnings per share (EPS) of $0.30 and adjusted diluted EPS of $0.22. Net income was $203.4 million, resulting in a net income margin of 12.0%. Adjusted EBITDA was $256.9 million, with a margin of 15.1%. The company also reported operating income of $139.5 million, with an operating margin of 8.2%.
On a segment basis, VWR Distribution & Services generated net sales of $1,233.8 million, a reported increase of 5.0% compared to the prior year, with organic growth of 5.8%. Bioscience & Medtech Products reported net sales of $464.5 million, a reported increase of 3.5%, with organic growth of 3.6%.
Avantor has updated its fiscal 2026 guidance. The company now expects organic revenue growth to be between 0.75% and 1.25%, up from the previous range of -0.5% to +0.5%. Adjusted EPS guidance remains in the range of $0.81 to $0.83. The company also raised its free cash flow guidance to between $525 million and $550 million, up from the previous range of $500 million to $550 million.
As of September 30, 2026, total gross debt was $3,699.7 million, and cash and cash equivalents were $464.3 million. GAAP net leverage was 9.6x, and adjusted net leverage was 3.1x. Operating cash flow for the quarter was $195.1 million, and free cash flow was $156.2 million.
